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Introduction
Persistent left superior vena cava (LSVC) is a rare syn-
drome occurring in ca. 0.3% of the population without con-
genital heart defects. Most frequently this syndrome has 
no symptoms and is discovered incidentally during the au-
topsy or pacemaker or cardioverter-defibrillator implanta-
tion trials [1–3]. Ninety-two percent of cases show that the 
persistent left superior vena cava passes to the enlarging 
coronary sinus and subsequently to the right atrium. Left 
superior vena cava is observed in about 10% of the popu-
lation with congenital heart defects, in which 0.07–0.13% 
of the LSVC cases are accompanied by atresia of the proper 
right superior vena cava [4, 5]. The aforementioned cases 
show that LSVC is the only blood vessel which pumps out 
blood from the upper part of the body and may result in 
severe technical problems as well as the vena cava superior 
syndrome [1–4, 6–8]. According to the relevant literature, 
the anomalies described herein are frequently accompa-
nied by arrhythmic disorders, e.g. short PQ, syndrome of 
malfunctioning sinus node, ectopic atrial rhythms, total 
atrioventricular block and tachyarrhythmia [7]. 
Presence of the LSVC is a  direct result of improper 
venous system development in the early stage of embryo 
evolution. In the first weeks of life the two anterior es-
sential veins conduct part of the cranial blood. Analog-
ically, two posterior essential veins conduct blood from 
the lower body parts. At the end of the second month of 
the embryo’s life, after enablement of sinus venosus to 
the right atrium, both anterior essential veins form an 
anastomosis, which then transforms into the left bra-
chiocephalic vein. Disappearance of the left anterior es-
sential vein below the anastomosis may be observed at 
a later stage. Furthermore, the section above transforms 
into the left internal jugular vein. The right anterior es-
sential vein is preserved entirely and its frontal section 
forms the analogical right internal jugular vein. The sec-
tion below the right subclavian vein estuary transforms 
into the right brachiocephalic vein. Similarly, the section 
below the left brachiocephalic vein transforms into the 
LSVC [6–10]. 
Aim
The aim of this work was to determine the prevalence 
of LSVC and its impact on the course and the number of 
complications during PM implantation.
Material and methods
Four examples of LSVC are described in this article, 
all detected during elective PM implantation in patients 
with symptomatic sinus node disease. In all cases a ve-
nography examination was performed before the implan-
tation, which revealed LSVC presence. Data for 498 con-
secutive patients between 06.2010 and 06.2016 have 
been analysed retrospectively. 
Results
Case 1: A 58 cm electrode was inserted through the 
coronary sinus into the right ventricle and implanted at 
the base of the chamber. Subsequently a  58 cm atrial 
electrode was implanted in the right auricle. Six days 
after PM implantation an ventricular electrode disloca-
tion was observed. It led to reimplantation intervention 
during which the electrode was replaced with a  longer 
active fixation electrode (Figure 1 A).
Case 2: A  58  cm electrode was inserted through the 
coronary sinus into the right ventricle and implanted by the 
outflow of the chamber. Subsequently a 52 cm auricular 
electrode was implanted in the right atrium (Figure 1 B).
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Case 3: A 65 cm electrode was transferred to the right 
ventricle through the coronary sinus, where the electrode 
end was placed at 1/3 of the inferior intraventricular sep-
tum (IVS). Subsequently a 52 cm atrial electrode was in-
serted into the right atrium (Figure 1 C).
Case 4: A 58 cm electrode was inserted through the 
coronary sinus into the right ventricle and implanted at 
the base of the chamber. Due to persistent atrial fibrilla-
tion a VVI-type pacemaker was implanted (Figure 1 D).
In all cases proper working parameters of the elec-
trodes were achieved with the devices programmed ac-
cording to current treatment guidelines. The electrodes 
were mounted using an active fixation lead in order to 
mitigate the risk of dislocation. DDDR-type stimulators 
were used in cases 1–3 and a  VVI-type pacemaker in 
case 4. All devices were programmed according to cur-
rent guidelines. Treatment results in all 4 cases were pos-
itive. No electrode function disorders or dislocations have 
been observed in long-term follow-up. 
Discussion
Left superior vena cava presence can be detected by 
a contrast examination. It usually does not result in major 
clinical challenges, but may cause technical access issues 





Anna Żabówka et al. Pacemaker implantation in persistent left superior vena cava
172 Advances in Interventional Cardiology 2017; 13, 2 (48)
during implantation of the trans-venous pacing system. 
Nonetheless, in most cases PM/CD implantation through 
the left subclavian vein is successful. PM/CD implemen-
tation through the right subclavian vein or epicardial elec-
trodes may be used in rare cases [1, 4, 5, 9, 11–13]. In addi-
tion to the above, the operator might consider alternative 
solutions such as insertion via the inferior vena cava (IVC) 
route or application of a  new-generation miniaturized 
trans-catheter pacing system (leadless pacemaker).
The points above are confirmed by Biffi in his 10-year 
study named “Left Superior Vena Cava Persistence in Pa-
tients Undergoing Pacemaker or Cardioverter-Defibrilla-
tor Implantation”. The study revealed that PM/ICD solu-
tion durability does not differ from the overall population 
in the case of patients with LSVC [1]. Petraca comes to 
similar conclusions in his twin 10-year study titled “Per-
sistent Left Superior Vena Cava in Patients Undergoing 
Cardiac Device Implantation: Clinical and Long-Term 
Data”. Petraca states that long-term stimulation system 
functioning is mainly dependant on coexisting heart dis-
eases, but the sole cardiac device implantation may be 
disrupted by LSVC presence [14]. 
Observation results lead to the conclusion that ve-
nography is the essential and quickest examination to 
confirm LSVC, although appliance of the contrasting fluid 
can result in negative side effects such as nausea, vom-
iting, skin allergy or gastric allergy including anaphylactic 
shock. Exclusion or confirmation of coexisting cardiac 
abnormalities is an important positive side benefit of 
venography examination. Furthermore, the observation 
shows that coronary angiography executed before im-
plantation of stimulating devices facilitates the latter. In 
certain cases it enables the implantation to take place 
at all. Coronary angiography also results in shortening of 
the following implantation time and reduces the risk of 
complications such as emphysema or hematoma caused 
by an early artery puncture. 
Left superior vena cava constitutes a surprise to the 
operators in most cases; hence proper patient prepara-
tion, correct device selection and overall operator’s ex-
perience were found to be the critical success factors in 
stimulating device implantation. Observations described 
herein included 498 implantation cases, out of which 
4 were diagnosed as LSVC (a higher frequency than that 
described in the literature – 0.8% vs. 0.3%). The anomaly 
did not result in any symptoms perceivable to the pa-
tients and each time its discovery was incidental. Left 
superior vena cava occurrence requires a  high level of 
attention from the operator as it may cause certain diffi-
culties in the implantation process. 
Conclusions
Left superior vena cava presence complicates the pro-
cedure and may result in significant extension of time 
needed for introduction and mounting of electrodes as 
well as increasing the risk of peri- and post-interven-
tional complications. However, the examples described 
in this article prove that successful artificial stimulation 
system insertion without serious complication is possible 
even if a persistent LSVC has been detected. To conclude 
– there is no single and definitive procedure that can be 
recommended if LSVC is detected. The most significant 
factor of success is the experience of the operator, which 
might help significantly in finding an alternative solution.
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